Omnix Medical

Company Overview

Snapshot

Founded in May 2015 by Moshik Cohen-Kutner and Niv Bachnoff, Omnix Medical operates with 11–50 employees. The company has raised $52.9M across 6 funding rounds from 11 investors.

Business overview

Omnix Medical is a clinical-stage biopharmaceutical company focused on developing next-generation anti-infective drugs. The company's core technology mimics the innate immune system of insects to eliminate bacteria, offering therapies designed to be resilient against resistance development. Omnix Medical's lead compound, OMN6, is a novel antimicrobial peptide (AMP) being developed for the treatment of life-threatening hospital-acquired infections (HIA) caused by Gram-negative bacteria like Acinetobacter baumannii. It serves the pharmaceutical and healthcare industries, operating within the Health Tech & Life Sciences sector, specifically in Drugs Discovery & Development.

Strategic signal

In June 2026, Omnix Medical announced the dosing of the first patients in its. This milestone signifies significant progress in the clinical development of their novel anti-infective, indicating a strong move towards potential market validation and addressing the urgent unmet need for new life-saving drugs against resistant bacteria. For investors, this signals advancement in their pipeline and potential for future commercialization.

Company Intelligence Q&A

What was a key recent development for Omnix Medical's lead compound?

In June 2026, Omnix Medical announced that the first patients were dosed in the.

What strategic initiative is Omnix Medical leading in Europe?

In July 2026, Omnix Medical was selected to lead a European consortium focused on accelerating the late-stage development of its experimental treatment for drug-resistant hospital infections.

Which investors participated in Omnix Medical's November 2020 funding round?

In November 2020, Omnix Medical completed a funding round with participation from Entrée Capital.